Hörr, Ingmar 1968-
Ingmar Hoerr deutscher Biologe und Unternehmer
Hoerr, Ingmar, 1968-
Hörr, Ingmar
VIAF ID: 67332751 (Personal)
Permalink: http://viaf.org/viaf/67332751
Preferred Forms
-
100 1 _
‡a
Hoerr, Ingmar,
‡d
1968-
-
100 1 _
‡a
Hörr, Ingmar
‡d
1968-
-
100 1 _
‡a
Hörr, Ingmar
-
100 0 _
‡a
Ingmar Hoerr
‡c
deutscher Biologe und Unternehmer
4xx's: Alternate Name Forms (9)
5xx's: Related Names (3)
- 510 2 _
‡a
CureVac AG
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
- 551 _ _
‡a
Neckarsulm
‡4
ortg
‡4
https://d-nb.info/standards/elementset/gnd#placeOfBirth
- 551 _ _
‡a
Tübingen
‡4
ortw
‡4
https://d-nb.info/standards/elementset/gnd#placeOfActivity
Works
| Title | Sources |
|---|---|
| 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one |
|
| Characterization of the ribonuclease activity on the skin surface |
|
| Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy |
|
| In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies |
|
| Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients |
|
| Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy |
|
| Der Mann, der das Impfen neu erfand, 2021: |
|
| Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas |
|
| Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. |
|
| RNA-Vakzine zur Induktion von spezifischen cytotoxischen T-Lymphozyten (CTL) und Antikörpern |
|
| Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial |
|
| Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study |
|
| A successful founder off the beaten path |
|
| Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. |
|
| Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. |
|
